BBLGWライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 6月 2024 @ 05:00):
Our systems believe the stock currently is undervalued by 1.24% compare to its pairs and should correct upwards.

Stats
本日の出来高	143
平均出来高	658
時価総額	1.32M
EPS	$-1.310 ( Q1 \| 2024-05-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-298.47 (Sector) 42.63 (Industry) 43.86
ATR14	$0 (0.00%)

ABMD 0.00%

AMIX -4.95%

BBLGW -21.85%

BVS 0.52%

COCH 3.06%

DHAI -3.26%

DHAIW -22.93%

DNAY 8.33%

EYES -5.05%

GBS -1.58%

HSCS -1.70%

HSCSW -32.26%

IINNW 1.61%

INVO -3.33%

LFWD 1.26%

MDAI -2.22%

MGRM 3.86%

MXCT -2.00%

NVNOW -32.98%

NXL -42.91%

NXLIW -15.00%

OSA -7.35%

OSAAW -6.40%

PAVMW 105.67%

PAVMZ 0.00%

PETVW 0.00%

QTI 2.21%

QTNT 0.00%

Insider Trading

Date	Person	Action	Amount	type
2024-01-17	Walsh Deina H	Buy	12 500	Employee Stock Option
2024-01-17	Frelick Jeff	Buy	25 000	Employee Stock Option
2024-01-08	Gagnon Robert E.	Buy	8	Non-Employee Stock Option
2024-01-08	Gagnon Robert E.	Buy	9	Non-Employee Stock Option
2024-01-08	Gagnon Robert E.	Sell	0	Common Stock

INSIDER POWER
34.04
Last 92 transactions
Buy: 61 917 793 \| Sell: 15 856 455

相関 (AI algo v.1.1b): Undervalued: 1.24% $44.04 paired level. (アルゴリズムは、最も相関の高い株式の変更をリアルタイムで追跡し、即時の更新を提供します)

Bone Biologics 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Bone Biologics 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-34.01

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-34.01

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$14.62

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Bone Biologics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.